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Abstract
A safe and efficacious cancer medicine is necessary due to the increasing population of cancer patients whose particular
diseases cannot be cured by the currently available treatment. Adenoviral (Ad) vectors represent a promising therapeutic
medicine for human cancer therapy. However, several improvements are needed in order for Ad vectors to be effective
cancer therapeutics, which include, but are not limited to, improvement of cellular uptake, enhanced cancer cell killing
activity, and the capability of vector visualization and tracking once injected into the patients. To this end, we attempted to
develop an Ad as a multifunctional platform incorporating targeting, imaging, and therapeutic motifs. In this study, we
explored the utility of this proposed platform by generating an Ad vector containing the poly-lysine (pK), the herpes
simplex virus type 1 (HSV-1) thymidine kinase (TK), and the monomeric red fluorescent protein (mRFP1) as targeting, tumor
cell killing, and imaging motifs, respectively. Our study herein demonstrates the generation of the triple mosaic Ad vector
with pK, HSV-1 TK, and mRFP1 at the carboxyl termini of Ad minor capsid protein IX (pIX). In addition, the functionalities of
pK, HSV-1 TK, and mRFP1 proteins on the Ad vector were retained as confirmed by corresponding functional assays,
indicating the potential multifunctional application of this new Ad vector for cancer gene therapy. The validation of the
triple mosaic Ad vectors also argues for the ability of pIX modification as a base for the development of multifunctional Ad
vectors.
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Introduction
Cancer remains the second leading cause of death worldwide,
and accounted for approximately 7.9 million deaths (13% of all
deaths) in 2007 according to the World Health Organization
(WHO, ‘‘The top 10 causes of death’’). Gene therapy represents a
new paradigm in the treatment of human diseases by the insertion
of genetic materials into individuals’ cells for therapeutic purposes
[1]. Among all treatment methods for cancer, gene therapy
represents a novel molecular measure that has the potential of
anti-tumor efficacy with selectivity and safety [2].
To date, 65.2% of all gene therapy clinical trials have targeted
cancer [3]. Among a number of cancer gene therapy strategies,
however, very few of them have shown a potent therapeutic effect
in human patients. In addition to the complexity and ambiguity of
tumorigenesis, other obstacles that may account for the failure of
many cancer gene therapy applications include the low transduc-
tion efficiency of the anti-cancer agents and the inability to
transduce the entire tumor cell population; the poor selectivity and
lack of long-term duration of anti-cancer agents in tumors
resulting in poor therapeutic efficiency as well as safety issues.
The concept of tumor cell targeting addresses these obstacles and
may represent a major improvement in the development of gene
therapy as an anti-cancer therapeutic. Given efficient targeting,
this anti-cancer agent may not only achieve highly selective and
specific tumor cell killings, but also avoid uptake by normal cells
and subsequent toxicity. An in vivo imaging modality, which
provides a means to study the distribution (e.g. accumulation,
spread, retention, and etc.) of anti-cancer therapeutics, can address
key issues that are fundamental to the design and test of novel anti-
cancer therapies, especially for replicative virus-based therapeutics
[4–7]. To combine these functionalities, and in an effort to create
more potent and reliable anti-cancer therapeutics, we attempted to
generate a multifunctional adenoviral (Ad) vector for the detection
and treatment of cancer. This Ad incorporates targeting, imaging
and cancer therapeutic modalities.
Ad is one of the most commonly used viral vectors in numerous
cancer gene therapy clinical trials [3]. In these studies, the use of
first- or second-generation adenoviral vectors has demonstrated
therapeutic transgene expression, but the overall clinical efficacy
has been poor due to the abovementioned limitations. To
overcome the limitations, many efforts have been focused on
modifying the Ad capsid on an individual cancer type basis. For
example, modification of the Ad capsid with targeting ligands
directed against tumor antigens boosted Ad transduction in tumor
cells in vitro and in vivo [8,9]. Other efforts aiming at Ad
visualization and tracking resulted in labeling the Ad capsid with
bioluminescence or fluorescence. This strategy allowed for
dynamic and direct monitoring of the physical location and
replication of viral particles in vivo [4,10,11]. Moreover, the
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kinase (TK) on the Ad capsid surface allowed for the direct
functional application of this protein in suicide gene therapy and
microPET imaging [12].
Our lab and others have validated the accommodating role of
Ad type 5 minor capsid protein IX (pIX) for the incorporation and
functional display of heterologous polypeptides and proteins, such
as poly-lysine (pK) [13], green and red fluorescence proteins (GFP
and RFP) [4,10,11], or HSV-1 TK [12,14]. We have further
demonstrated the possibility of creating a triple mosaic Ad by
presenting three different heterologous epitopes at pIX locales on
a single Ad vector using genetic or non-genetic modifications [15].
In this study, we explored pIX to display three functional epitopes
– pK (for targeting), monomeric RFP (mRFP1) (for imaging), and
HSV-1 TK (for therapeutic) on a single Ad vector in our effort of
generating multifunctional Ad vectors.
Materials and Methods
Antibodies
The pIX-specific antibody was a kind gift from Dr. I. Dmitriev
(Gene Therapy Center, University of Alabama at Birmingham).
The rabbit polyclonal anti-TK antibody was a kind gift from Dr.
J.M. Mathis (Gene Therapy Program, Department of Cellular
Biology and Anatomy, LSU Health Sciences). The mouse anti-
His6 monoclonal antibody was purchased from Qiagen (Valencia,
CA.). The goat polyclonal anti-His6 antibody was purchased from
Abcam (Cambridge, MA.). The anti-Flag M2 monoclonal
antibody and the rabbit polyclonal anti-c-myc antibody were
purchased from Sigma (St. Louis, MO.). The rabbit polyclonal
anti-RFP antibody was purchased from Chemicon (Temecula,
CA.). Horseradish peroxidase (HRP)-conjugated goat anti-mouse
and goat anti-rabbit secondary antibodies, alkaline phosphatase
(AP)-conjugated goat anti-mouse, goat anti-rabbit secondary
antibodies, and electron microscopy (EM) grade 18 nm colloidal
gold-conjugated donkey anti-goat antibody were purchased from
Jackson ImmunoResearch Laboratories Inc. (West Grove, PA.).
EM grade 10 nm gold-conjugated donkey anti-mouse, and EM
grade 25 nm gold-conjugated donkey anti-rabbit secondary
antibodies were purchased from Electron Microscopy Science
(EMS, Ft. Washington, PA.).
Cells
The human embryonickidneycells (293),human lung carcinoma
cells (A549), and human breast cancer cells (AU-565) were
purchased from American Type Culture Collection (ATCC,
Manassas, VA.). All cell lines were maintained at 37uCi na5 %
CO2 humidified incubator. The AU-565 cells were cultured in
RPMI-1640 (2 mM L-Glutamine, 10 mM HEPES, 1 mM Sodium
pyruvate, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, 100 units/
ml of penicillin, 100 mg/ml of streptomycin, 10% Fetal Bovine
Serum). All other cell lines were cultured in Dulbecco’s modified
Eagle medium-Ham’s F12 (50/50) medium (Sigma) containing
10% fetal calf serum (HighClone, Logan, Utah), 2 mM L-
glutamine, 100 units/ml of penicillin, 100 mg/ml of streptomycin.
Construction of Recombinant Plasmids
(i) Generation of shuttle plasmids. All parental plasmids were
acquired from commercial sources or have been character-
ized previously: pShlpIXNhe [13], pShuttle-IX-mRFP1 [4],
pShuttle-IX-flag-sr39tk [12], pShuttle-CMV and pAdEasy-1
(Stratagene, La Jolla, CA). The shuttle plasmids were
constructed using restriction and PCR cloning as following.
pShldpIX = pShlpIXNhe/BglII/NheI/blunt/SL (self liga-
tion); The PCR product (pcrIXpK) containing the coding
sequence of pIX-pK fusion protein was generated by using
pShlpIXNhe as a template and primers 59-GGGGTAC-
CGGGCGTGGTTAAGGGTG and 59-GGGGTACCTT-
TATTTATGTTCTTGTCATCGTCATCCTTATAATC;
pShlpIXflagpK = pShldpIX/KpnI + pcrIXpK/KpnI. The
PCR product (pcrH6TK) containing the coding sequence of
H6-sr39tk protein was generated by using pShuttle-IX-flag-
sr39tk as a template and primers 59-CTAGCTAGCCAC-
CATCACCATCACCAT CTAGCCGGATCCGGTTC
and 59-CTAGCTAGCTCAATTAGCCTCCCCCATC;
pShlpIXH6TK = pShlpIXNhe/NheI + pcrH6TK/NheI.
The PCR product (pcrMycmRFP1) containing the coding
sequence of c-myc-mRFP1 protein was generated by using
pShuttle-IX-mRFP1 as a template and primers 59- CTAGC-
TAGCGGCGG AGGGAGCGAGCAGAAACTCATCT-
CTGAAGAAGATCTGGGAAGCGCCTCCTCCGAG-
GACGTCAT and 59- CTAGCTAGCTTAGGCGC-
CGGTGGAGTG; pShlpIXmycmRFP1 = pShlpIXNhe/
NheI + pcrMycmRFP1/NheI. All clones were verified by
restriction digestion and sequencing.
(ii) Generation of pIX-modified adenoviral genomes by homol-
ogous recombination in Escherichia coli [16]. The shuttle vectors
pShlpIXflagpK, pShlpIXH6TK, and pShlpIXmycmRFP1
were linearized with PmeI restriction enzyme and homolo-
gously recombined with pAdEasy-1 in electrocompetent
BJ5183-AD1 (Stratagene, La Jolla, CA). The generated
adenoviral genome contains IX-pK, IX-sr39tk, or IX-mRFP1
modified pIX gene in deleted E1 region. The constructs of
resultant Ad plasmids pAdpIXflagpK, pAdpIXH6TK, and
pAdpIXmycmRFP1 were confirmed by restriction digestion
and sequencing.
Virus Rescue, Propagation and Purification
pAdpIXflagpK, pAdpIXH6TK, and pAdpIXmycmRFP1 plas-
mids were linearized with PacI restriction enzyme and transfected
into 293 cells grown in 25-cm
2 flasks using Lipofectamine
TM 2000
(Invitrogen, Carlsbad, CA). The cells were collected when evident
cytopathic effect (CPE) was observed followed by disruption using
four freeze and thaw cycles. The lysates were centrifuged at
3,0006g for 5 min at 4uC to remove cellular debris. The released
viruses in the supernatant were subsequently used for further
propagation until a sufficient amount of 293 cells were infected
(ten 175-cm
2 flasks). The Ad in infected cells were purified
essentially as described previously [15]. In brief, the cells were
lysed by four freeze and thaw cycles and centrifuged at 3,8006g
for 30 min at 4uC to remove cellular debris. The cell extracts
containing the viruses were loaded on the top of a 1.33/1.45 CsCl
step gradient and centrifuged at 55,0006g for 3 hours at 4uC. The
lower band, containing infectious virus particles, was re-centri-
fuged on another 1.33/1.45 CsCl step gradient at 100,0006g
overnight at 4uC. The resulting band of adenoviruses was collected
and dialyzed four times against 500 ml phosphate buffered saline
(PBS) containing 10% glycerol, 2 hours each time. The generated
Ads were designated as Ad-IX-flag-pK, Ad-IX-H6-sr39tk, and
Ad-IX-myc-mRFP1. Viral particle (VP) titers were determined by
spectrophotometry at OD260 using standard procedures [17].
Generation of Triple pIX-Modified Ad by Co-Infection
Ten 175-cm
2 flasks of 293 cells were infected with Ad-IX-flag-
pK, Ad-IX-H6-sr39tk, and Ad-IX-myc-mRFP1 at a total MOI of
200–300 VP/cell. The infected cells were collected for Ad
purification as described in above.
Triple Mosaic Ad Vector
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5610
9 VP of purified viruses were boiled in Laemmli sample
buffer for 5 min and separated on 4 to 15% gradient sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Separated proteins were then transferred to polyvinylidene
difluoride (PVDF) membranes, which were blocked in 5% skim
milk in Tris-buffered saline containing 0.05% Tween-20 (TBS-T)
followed by incubation with primary antibodies (mouse anti-Flag,
1:1000; rabbit anti-TK, 1:500; rabbit anti-RFP, 1:500). After
washing and re-blocking, the membrane was incubated with the
appropriate secondary antibodies conjugated to Horse Radish
Peroxidase (HRP) at 1:1000 dilution. The HRP signal was
developed with ECL plus Western blotting detection system (GE
healthcare, Little Chalfont, UK), and then detected with BioMax
MR scientific imaging films (Kodak, Chalon-sur-Saone, France)
and a medical film processor SRX-101A (Konica, Tokyo, Japan).
ELISA
Solid-phase binding enzyme-linked immunosorbent assays
(ELISAs) were performed essentially as described previously
[18]. Briefly, 10
9 VP of viruses were subjected to serial dilution
(1, 2, 4, 8, 16, 32, 64, 128) in 100 ml of 100 mM carbonate buffer
(pH 9.5), and immobilized in triplicate in a 96-well plate (Nunc
Maxisorp) by overnight incubation at 4uC. After 4 washes with
TBS-T and blocking with TBS-T containing 2% bovine serum
albumin (BSA), the viruses were probed with primary antibody,
and then AP-conjugated secondary antibodies in TBS-T contain-
ing 0.5% BSA at room temperature for 2 hours, with extensive
washes and blocking in between. p-nitrophenyl phosphate (Sigma)
was used for color development as described by the manufacturer,
and light absorbance (405 nm) was obtained by a microplate
reader (PowerWave HT 340, BioTek, Winooski, VT.) after
incubation for 150 min at room temperature.
Immunoelectron Microscopy
Immunoelectron microscopy was performed essentially as
described previously [15]. Briefly, the viruses were adhered to
400-mesh nickel grids supported with carbon-coated Formvar film
(EMS). After washing with 1% BSA/PBS twice for 10 min each,
grids were probed with 1% BSA/PBS diluted primary antibodies
(1:200 M2 anti-Flag, goat anti-His6, and rabbit anti-c-myc) and
incubated at room temperature for 1 hour. After 2 cycles of 1%
BSA/PBS washes, grids were incubated with 1:10 diluted
secondary antibodies (10 nm gold-donkey anti-mouse, 18 nm
gold-donkey anti-goat, and 25 nm gold-donkey anti-rabbit) at
room temperature for 45 min. After fixing with 1% glutaralde-
hyde/PBS for 20 min, grids were subjected to negative staining
in 2% uranyl acetate for 12 seconds and examined under
transmission electron microscope at 60 KV in the UAB High
Resolution Imaging Facility.
Cell Binding Inhibition Assay
The binding inhibition assay was performed essentially as
described previously [13]. AU-565 cells were released from flasks
using Versene, washed once with PBS, and pelleted and
resuspended to 0.5610
7 cells/ml in binding buffer (DMEM/F12
with 1% BSA). 100 ml cell aliquots were transferred into each 5 ml
test tube, and were added with 50 ml of an inhibitor (soluble CAR
(sCAR), heparin, or PBS). After 30 min shaking at 4uC, viruses at
a multiplicity of infection (MOI) of 500 VP/cell in 50 ml binding
buffer were added into each tube, and they were shaken at 4uC for
1.5 hours. The cells were washed once with 4 ml of binding buffer,
and their total DNA was extracted and subjected to quantitative
Real-time PCR (TaqMan) to measure Ad5 E4 copy number.
Total DNA in each sample was quantified by OD260.
Cell Killing Assay
The cell killing assay was performed essentially as described
previously [12]. The lung carcinoma A549 cells were seeded on a
96-well plate at a density of 10,000 cells/well one day before Ad
infection. Ad vectors carrying pIX-TK fusion proteins at various
MOIs were then used to infect A549 cells. After 2 hours or
12 hours of incubation, the prodrug, ganciclovir (GCV) (GYTO-
VENE-IV, Roche Laboratories, Nutley, NJ), was added to the
cells at a final concentration of 1 mM. After 24 or 48 hours of
incubation, the viability of A549 cells was evaluated using
CellTiter 96H AQueous Non-Radioactive Cell Proliferation Assay
kit (Promega, Madison, WI) and a microplate reader (PowerWave
HT 340, BioTek, Winooski, VT) in accordance with the
manufactories’ instruction.
Statistical Analysis
Statistical analysis was performed using two-tailed unpaired
Student’s t-tests between groups. P values ,0.05 were considered
statistically significant.
Results
Generation of a Triple pIX-Modified Ad by Co-Infection
In order to generate the triple pIX-modified Ad carrying poly-
lysine (pK), HSV-1 thymidine kinase mutant (HSV-1 sr39tk), and
monomeric red fluorescent protein (mRFP1) by co-infection, three
parental viruses were generated first: Ad-IX-Flag-pK, Ad-IX-H6-
TK, and Ad-IX-myc-mRFP1. These three viruses express pIX-
pK, pIX-TK, or pIX-mRFP1 fusion protein with Flag, His6,o rc -
myc tag, respectively (Fig. 1A). Unless specified, all viruses used in
the study are replication-incompetent (E1/E3 deleted), and the
transcription of modified pIX genes in each parental virus was
driven by the endogenous pIX promoter. In addition, pIX-
modified Ads only express the pIX fusion protein since the native
pIX genes have been replaced with the modified pIX genes. The
three parental viruses were used to co-infect 293 cells that support
Ad replication to generate the triple pIX-modified virus. Since the
three different pIX fusion proteins were all expressed and could be
assembled into each viral particle, the resultant virions were
expected to contain a mixture of three types of pIX fusion proteins
(Fig. 1B). The generated and CsCl-purified Ad progenies
(designated as coAdpIXPTM#1) had a normal yield compared
to single pIX-modified Ads in our laboratory (data not shown).
The incorporation of pIX fusion proteins was analyzed by
Western blotting with anti-Flag, anti-RFP, and anti-TK antibod-
ies. The detection of pIX fusion protein bands with expected
molecular masses confirmed that three pIX fusion proteins (i.e.
pIX-pK, pIX-TK, and pIX-mRFP1) were contained in the viral
particles of purified viral pool (Fig. 1C).
Surface Display of Modified pIXs in Ad Particles
To test whether or not the polypeptides/proteins incorporated
into the C-terminus of pIX were presented on the viral surface and
accessible to antibodies, we performed enzyme-linked immuno-
sorbent assays (ELISAs). In the ELISA experiment, anti-Flag, anti-
His6, and anti-c-myc antibodies were used to detect the three types
of modified pIXs. The control Ad5 containing wild type pIX was
not recognized by any of these antibodies. The coAdpIXPTM#1
viruses were recognized by anti-Flag, and anti-c-myc antibodies
(Fig. 2). However, the viruses could not be recognized by either
anti-His6 antibody (Fig. 2) or anti-TK antibody (data not shown).
Triple Mosaic Ad Vector
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into the triple pIX-modified Ad vectors. The insignificant binding
of anti-His6 or anti-TK antibody to the viruses indicates that TK
was either not efficiently surface exposed on the viral capsids or the
accessibility of these two antibodies to TK proteins in such a
configuration was insufficient to be detected in ELISA.
Mosaicism of the Triple pIX-Modified Ad
Western blotting and ELISA analysis of the purified viral
particles demonstrated that three types of pIX fusion proteins were
incorporated into the Ad particles produced by co-infection
(Fig. 1). To examine whether a single Ad viral particle could
display all three types of functional proteins, we performed
Figure 1. Schema of Ad pIX modifications. (A) Constructs of the modified pIX genes in genomes of three parental viruses: Ad-IX-Flag-pK, Ad-IX-
H6-TK, and Ad-IX-myc-mRFP1. Modified pIX genes (tagged with the Flag, His6, and c-myc, respectively) were driven by the native pIX promoter. (B)
Structural diagram of triple pIX-modified Ad (coAdpIXPTM#1) generated by co-infection strategy. pK, TK, and mRFP1 peptides/proteins were
incorporated in the C termini of pIX. (C) Western blotting analysis of Ad vector containing triple pIX modifications. 5610
9 VPs of CsCl-purified control
Ad5 (lane 1) and the triple pIX-modified coAdpIXPTM#1 (lane 2) were subjected to SDS-PAGE. The separated proteins were stained with Gelcode
Blue (Pierce, Rockford, IL.) to detect the total viral proteins (left panel) or probed with anti-Flag, anti-RFP, or anti-TK antibody (right panel).
doi:10.1371/journal.pone.0008526.g001
Triple Mosaic Ad Vector
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modified Ad particles. Anti-Flag, anti-His6 and anti-c-myc
antibodies were used to detect pIX-pK, pIX-TK and pIX-mRFP1
proteins in the viral particles, respectively, followed by three
corresponding secondary antibodies conjugated with 10, 18, and
25 nm gold particles, respectively. As shown in Figure 3, no gold
particle was bound to the control Ad5 displaying wild type pIX,
while the Ad viral particles containing a single pIX fusion protein
(Ad-IX-Flag-pK, Ad-IX-H6-TK, and Ad-IX-myc-mRFP1) were
stained by corresponding gold particles. The triple modified
coAdpIXPTM#1 viruses were recognized by anti-Flag, anti-His6
and anti-c-myc antibodies and labeled with 10, 18 and 25 nm gold
particles. The results demonstrated that three types of pIX fusion
proteins could coexist on one single viral particle and were
exposed on the viral surface.
It is noteworthy that, although there are 240 copies of pIX
molecules in each viral particle, only a few gold particle-
conjugated antibodies were bound on the pIX-modified Ad viral
particles. This data was consistent with previous reports
[15,19,20]. This is probably due to the relative low accessibility
Figure 2. Incorporation and presentation of modified IX
proteins on the Ad capsid. ELISA analysis of Ad vector containing
triple pIX modifications. 10
9 VPs of CsCl-purified Ad5 (negative control)
or coAdpIXPTM#1 were subjected to a serial dilution (1, 1/2, 1/4, 1/8,
1/16, 1/32, 1/64, 1/128) and immobilized on an ELISA plate. The viruses
were probed with anti-Flag (1:2000), anti-His6 (1:1000), and anti-c-myc
antibodies (1:1000), followed by incubation with alkaline phosphatase-
conjugated secondary antibodies (1:1000). After color development, the
light absorbance was measured and plotted on the Y-axis against the
viral concentrations. Each point represents the mean and standard
deviation (SD) of triplicate determinations. Some error bars standing for
SD are smaller than their symbols.
doi:10.1371/journal.pone.0008526.g002
Figure 3. Immuno-gold electron microscopy on pIX-modified
Ad vectors. Control or pIX-modified Ad vectors were loaded onto EM
grids, probed with gold nanoparticle conjugated antibodies, and
observed under electron microscope at 60 KV. Mouse anti-Flag, goat
anti-His6, and rabbit anti-c-myc primary antibodies were used for
detecting three kinds of tags on pK, HSV-1 TK, and mRFP1, respectively.
10 nm gold-donkey anti-mouse, 18 nm gold-donkey anti-goat, and
25 nm gold-donkey anti-rabbit secondary antibodies were used for
subsequent gold labeling of Ad particles. Solid thin arrows indicate
10 nm gold particles, empty arrows indicate 18 nm gold particles, and
solid thick arrows indicate 25 nm gold particles. The scale bar in each
panel represents 50 nm in length.
doi:10.1371/journal.pone.0008526.g003
Triple Mosaic Ad Vector
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antibody-conjugated gold particles against each other during
staining. We chose large gold particles for easier differentiation
among three epitopes, which have even a higher antibody/gold
ratio and a higher spatial hindrance effect than that of small gold
particles which are commonly used. In addition, anti-His6
antibody does not efficiently bind pIX-TK as shown in Figure 2.
Furthermore, the low efficiency of triple staining may be another
reason of the scattered staining pattern shown in Figure 3.
Therefore, it is not surprising that the frequency of triply-labeled
Ads is low - only about 1% viral particles were stained with all
three types of gold particles (Table 1).
Targeting Activity of Incorporated Poly-Lysine on the
Triple pIX Mosaic Ad
Ad5 has been demonstrated to bind its primary cellular
receptor, the coxsackie B virus and adenovirus receptor (CAR),
as the initial step of infection via its fiber knob protein [23]. The
poly-lysine (pK) incorporated into pIX locales in AdLucIXpK has
been shown to mediate Ad interaction with cellular heparan
sulfate proteoglycans (HSPGs), resulting in CAR-independent
virus-cell binding and transduction [13]. Therefore, in order to
examine whether the pK peptides incorporated into the triple pIX
mosaic Ad vector had similar targeting activity to HSPGs, we
performed cell binding and inhibition assays with CAR-deficient
(low level of CAR) AU-565 cells in the presence or absence of
heparin or soluble CAR (sCAR) protein.
Another version of the triple pIX-modified Ad vector was created
using three previously characterized parental pIX-modified viruses:
AdLucIXpK [13], Ad-dE1-IX-sr39tk [12], and Ad-IX-mRFP1 [4]
(Flag tags were present in all three pIX fusion proteins). The
incorporation of pIX-pK, pIX-TK, and pIX-mRFP1 proteins on
the derived triple mosaic Ad (designated as coAdpIXPTM#2) was
verified by Western blotting on the purified viruses using anti-Flag,
anti-RFP, and anti-TK antibodies (Fig. 4C).
It was observed that the positive control AdLucIXpK, in which
all pIX molecules were modified by pK, exhibited as much as two
times of cell binding on CAR-deficient AU-565 cells compared to
wild type Ad5. The triple mosaic Ad5 (coAdpIXPTM#2), in
which only a portion of pIX molecules contained pK modification,
showed approximately 1.5-time higher cell binding activity
compared to wild type Ad5 (Fig. 5). In addition, more than
90% cell binding ability of AdLucIXpK and 50% of the
coAdpIXPTM#2 were inhibited by free heparin at a final
concentration of 500 ug/ml, while the cell binding of the control
Ad5 was not significantly affected (Fig. 5). The addition of 200 mg/
ml sCAR inhibited more than 80% cell binding of control Ad5,
while having a relatively modest effect on AdLucIXpK (60%) and
coAdpIXPTM#2 (25%) (Fig. 5). Together, our data suggest that
the pK peptides displayed on coAdpIXPTM#2 capsids could
mediate CAR-independent cell targeting through the interaction
with cellular heparan sulfate receptors.
Enzymatic Activity of Incorporated TK on Triple pIX
Mosaic Ad
HSV-1 TK protein can be genetically incorporated into Ad at
pIX locales with its native enzymatic activity retained, which can be
used for cancer gene therapy with prodrug ganciclovir (GCV), and
can be utilized for in vitro and in vivo imaging when coupled with
microPET system [12,14]. To investigate whether the pIX-TK
fusion proteins could function normally, we evaluated TK-induced
cytotoxicity in the presence of GCV at a pharmacologic
concentration by MTS assay. To evaluate the pIX-TK fusion
protein directly released from Ad particles after successful cellular
entry,lungcarcinomaA549 cellswereused,inwhichthereplication
of non-replicative Ad and the pIX gene expression are minimal.
A549 cells were infected with single pIX-modified Ad (Ad-dE1-IX-
sr39tk) or triple pIX mosaic Ad (coAdpIXPTM#2) at various
MOIs. GCV was added in infected cells two hours post infection,
and the cell death mediated by pIX-TK fusion protein was
evaluated by MTS assay 24 hours thereafter. The data suggested
that there was significant GCV-associated cytotoxicity induced by
either Ad-dE1-IX-sr39tk or coAdpIXPTM#2 infection at a high
MOI (10,000 VP/cell) (Fig. 6A). However, at a lower MOI (5000
VPs/cell), only Ad-dE1-IX-sr39tk infection showed GCV-induced
significant cytotoxicity. This indicated that the pIX-TK activity in
the triple pIX-modified Ad was lower than that of single pIX-TK-
modified Ad, which may be attributable to the copy number
differences of pIX-TK incorporated in the viral particles.
We then extended the viral incubation time (12 hours) prior to
GCV addition as well as the GCV treatment time (48 hours). We
found that both Ad-dE1-IX-sr39tk and coAdpIXPTM#2 induced
significant cytotoxicity at a medium and a high MOI, indicating
that a longer time of viral incubation and GCV treatment could
enhance the pIX-TK mediated cytotoxicity (Fig. 6B). Altogether,
our data suggested that there was a modest effect of the pIX-TK in
the triple pIX-modified Ad since high MOI had to be used. The
data also suggested that the triple-pIX modified Ad was functional
in cell killing.
Fluorescent Activity of Incorporated mRFP1 on the Triple
pIX Mosaic Ad
Ad vectors labeled with fluorescent proteins (e.g. GFP and
mRFP1) have been demonstrated to be useful imaging tools to
Table 1. Summary of immunogold staining of coAdpIXPTM#1.
Epitopes to be detected Flag His6 c-myc Flag+His6 Flag+myc His6+myc Triple
Properties of gold-labeled antibodies*
Size of gold particle (nm) 10 18 25
Antibody/gold ratio 7–12 N/A 115–180
Statistics of staining
The number of viral particles with positive staining 210 13 12 12 11 2 2
Percentage of viral particles with positive staining over total viral particles (%) 98.13 6.07 5.61 5.61 5.14 0.93 0.93
N/A = not available.
*Provided by the manufacturer.
The counting was performed in eleven electron microscopy images that totally contain 214 viral particles.
doi:10.1371/journal.pone.0008526.t001
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vitro and in vivo [4,10,11,24]. To confirm the fluorescent signal of
pIX-mRFP1 proteins displayed on the triple pIX mosaic Ad, A549
cells were infected with the virus, and the mRFP1 activity was
monitored by fluorescence microscopy one hour post infection.
The result showed that pIX-mRFP1 proteins associated with the
triple pIX mosaic Ad capsid (coAdpIXPTM#1) retained their
fluorescent activity, but was lower than that from Ad-wt-IX-
mRFP1 (Fig. 7).
Discussion
Treatment of tumors remains a lofty task and a long time battle
in our medical community. With the hope of overcoming the
inefficiency and toxicity of conventional therapies, cancer gene
therapy has provided diverse strategies and molecular techniques
as armors in the battle. In our previous work we have utilized
approaches based upon dual expression cassettes to achieve fiber
mosaic particles [25–27]. In these studies a frequent technical
challenge has been the achievement of an expression stoichiometry
that allowed mosaic particles with full representation of the capsid
protein variants. In our current studies, we have advanced this
aspect of the approach to better optimize adequate expression of
each capsid protein construction.
Figure 4. Western blotting analysis of coAdpIXPTM#2. (A) Constructs of the modified pIX genes in genomes of three parental viruses:
AdLucIXpK, Ad-dE1-IX-sr39tk, and Ad-IX-mRFP1. Modified pIX genes (tagged with the Flag) were driven by the native pIX promoter. (B) Structural
diagram of triple pIX-modified Ad (coAdpIXPTM#2) generated by co-infection strategy. (C) 5610
9 VPs of CsCl-purified control Ad5 (lane 1) and the
triple pIX-modified coAdpIXPTM#2 (lane 2) were subjected to SDS-PAGE. The separated proteins were stained with Gelcode Blue (on the left) or
probed with anti-Flag, anti-RFP, or anti-TK antibody. A long-exposure of the anti-Flag blot was included to show pIX-pK protein, which is incorporated
into Ad particles at a very low level. The ‘‘*’’ asterisks indicate degradation products of pIX-mRFP1 fusion protein.
doi:10.1371/journal.pone.0008526.g004
Figure 5. Cell Binding of the triple pIX-modified Ad vector. AU-
565 cells were incubated with Ad5, AdLucIXpK, or coAdpIXPTM#2a ta n
MOI of 500 VP/cell in the presence of 500 mg/ml heparin or 200 mg/ml
sCAR protein at 4uC. Bound Ad particles were quantified by quantitative
real-time PCR and normalized with total cellular DNA. Each bar
represents the mean and SD of triplicate determinations, and asterisks
indicate significant difference between specified groups.
doi:10.1371/journal.pone.0008526.g005
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strategy to derive mosaic Ad vectors that embody the multifunc-
tional principle central to our goal. The derived Ad vector carried
three distinct types of heterologous peptides/proteins at the minor
capsid protein IX locales, which are pK, HSV-1 TK, and mRFP1,
whereby function as targeting, tumor cell killing, and imaging
motifs and represent key features of an anti-cancer therapeutics.
The incorporation of three types of pIX fusion protein in the triple
mosaic Ad vector was demonstrated by Western blot and ELISA.
Electron microscopy was used to demonstrate that these three
types of pIX fusion protein were exposed on the viral surface and
could coexist in a single viral particle. Due to the nature of
aggregation of pIX-modified proteins [28], any affinity purifica-
tion-based method would be weak in the demonstration of the
mosaicism of three types of pIX on Ad capsid. Therefore, electron
microscopy is the most straightforward and unambiguous method
in the interpretation of the mosaicism despite low staining
efficiency. In addition, the pIX-pK displayed on the Ad capsid
could mediate HSPGs dependent binding to human breast cancer
cells (AU-565). Due to the lack of a proper reporter gene in the
triple pIX-modified Ad, we could not perform gene transfer assays
to validate the gene transfer enhancement of this virus. However, a
previous publication of our group showed that the pK-induced cell
binding enhancement correlates with the transduction enhance-
ment in several CAR-deficient cell lines (including AU-565 cell
line) [13]. Moreover, the viral capsid-incorporated pIX-TK could
induce cytotoxicity with GCV in lung carcinoma A549 cells, and
the capsid-incorporated pIX-mRFP1 could signal the localization
of viral particles in virus-infected cells. The activities of three types
of pIX fusion proteins were relatively low compared with their
parental single pIX-modified Ad vectors. These may be attribut-
able to several reasons. First, theoretically each type of pIX fusion
protein occupies one third of the total pIX locales in the triple pIX
mosaic Ad, resulting in a lower copy number of each type of pIX
fusion than single pIX-modified virus. Second, pIX fusion
proteins, at least pIX-EGFP and pIX-mRFP1, may be aggregated
to some extent in the Ad capsid [28]. Therefore, three types of pIX
fusion proteins may not be compatible with each other and are
susceptible to aggregation during viral assembly, which lowers the
activity of incorporated functional motifs. Taken together, these
Ad capsid-incorporated heterologous peptides/proteins, i.e. pK,
TK, and mRFP1, retained their functionalities and could therefore
serve as targeting, cell killing, and imaging motifs, respectively.
These results argued for the platform potential of the triple pIX-
modified Ad vector in building a multifunctional nanoparticle in
cancer gene therapy.
Furthermore, we would like to point out that we also explored a
genetic method as previously described [15] to construct the triple
pIX mosaic virus by replacing the wild type pIX gene with three
modified pIX genes, i.e. IX-pK, IX-TK, and IX-mRFP1, in the
Ad genome. Even though such generated triple pIX mosaic Ad
was successfully rescued and was appropriately propagated, severe
genome rearrangement occurred as analyzed by restriction
enzyme digestion (data not shown). These results suggest that
the insertion of three modified pIX genes with a total length of
,5kb in the deleted E1 region compromised the genomic stability,
probably due to the homologous recombination among three
adjacent pIX gene sequences.
Several factors need to be considered before utilizing the triple
mosaic Ad vector for cancer therapy. One factor is the stoichiometry
Figure 6. Cell killing effect of HSV-1 TK incorporated Ad
vectors. (A) A549 cells were infected with Ad5 (negative control), Ad-
dE1-IX-sr39tk, or coAdpIXPTM#2 at various MOIs. 2 hours later, prodrug
GCV was added onto cells with the final concentration at 1 mM.
24 hours later, the cell killing activity induced by converted GCV
mediated through pIX-TK was evaluated by MTS assay. Cells infected
with viruses were normalized with that of uninfected cells as relative
cell survival. (B) A549 cells were infected with single pIX-modified Ad-
dE1-IX-sr39tk or coAdpIXPTM#2 at various MOIs. 12 hours later, GCV
was added onto cells at the final concentration of 1 mM. 48 hours later,
the cell killing activity of TK/GCV was evaluated as same as described
above. Asterisks indicate a significant difference between specified
groups.
doi:10.1371/journal.pone.0008526.g006
Figure 7. Fluorescence microscopy of cells infected with the
triple pIX mosaic Ad vector. A549 cells were infected with wild type
Ad5, Ad-wt-IX-mRFP1 (containg wild type E1 promoter), or
coAdpIXPTM#1 at an MOI of 10,000 VP/cell, and the fluorescent signal
of pIX-mRFP1 was monitored 1 hour post infection (nuclei were
counterstained with Hoechst 33342). Fluorescent images were captured
using an Olympus IX-70 microscope with a 100X objective (oil lens). The
enlarged image of each rectangle area was presented underneath.
doi:10.1371/journal.pone.0008526.g007
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modified pIXs, i.e. pIX-pK, pIX-TK and pIX-mRFP1, have
different properties such as size, surface charge, structure and
conformation. Therefore, the modified pIXs are not likely to be
equally assembled even if equal expression levels were achieved (for
example, using a single set of in cis components to drive the co-
expression of three different pIX proteins, such as the Foot-and-
mouth disease virus 2A (FMDV-2A) elements [29–31]). As we have
observed in the anti-Flag (detects all modified pIXs) staining in
Figure4,pIX-mRFP1andpIX-TKfusionproteinsweremuchmore
abundantly incorporated into the Ad particles compared with pIX-
pK protein. Nevertheless, a potential merit of the co-infection
strategy is that the incorporation levels of three different pIXs in the
triple mosaic Ad vector could be adjusted to meet different
requirements in distinct applications, by altering the MOI of each
parental virus.
In addition to carrying targeting, therapeutic, and imaging
motifs (pK, HSV-1 TK, and mRFP1 in this study), the flexibility of
our multifunctional Ad vector platform is beneficial to the design
of viral vectors to fulfill other sophisticated tasks. For example,
better understanding of organ and tissue’s physical barriers makes
it possible to deliver viral vectors in vivo more efficiently than before
by utilizing various transcytosis machineries [32–36], which need
an extra relaying motif for transcytosis in addition to the targeting
ligand. Other tasks include but not limited to: a dual imaging
system coupled with Fluorescence Resonance Energy Transfer
(FRET) technology to maximize detection reliability and minimize
background [35,36]; a double targeting anti-cancer agent to
achieve enhancement in delivery and specificity [27].
Taken together, the potential of our radically designed and
novel mosaic adenoviral vectors has been clearly suggested. Our
study presented herein is a solid argument for the concept of
building a multifunctional cancer therapeutic particle based on
triple modifications on Ad, bearing in mind that much work is still
in need in terms of combining and optimizing the targeting/re-
targeting, imaging, and therapeutic functionalities within specific
tumor scenarios.
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